Apollomics Inc. is a development-stage biotechnology company founded in May 2015, focused on discovering and developing oncology drug candidates. Its most advanced product candidate is vebreltinib, a MET inhibitor requiring additional clinical development and regulatory approval. The company has no approved products or product sales revenue and is pursuing partnerships for development and commercialization, including a collaboration with LaunXP for vebreltinib in Asia.
38 total filings indexed. 38 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001944885 |
| Ticker | APLM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.apollomicsinc.com |
| Listed | 2023-03-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APLM (~200 tokens, structured JSON with cryptographic provenance)